Dupilumab (anti-IL-4Rα monoclonal antibody) is approved as an add-on therapy for which CRS phenotype?

• A CRS without nasal polyps (CRSsNP) unresponsive to antibiotics
• B Allergic fungal rhinosinusitis post-FESS
• C Acute exacerbation of CRS in non-atopic patients
• D Recurrent/refractory CRS with nasal polyps (CRSwNP) ✓

Explanation

Dupilumab blocks the shared IL-4/IL-13 receptor subunit (IL-4Rα), suppressing Type 2 inflammation driving eosinophilic CRSwNP. It is FDA/EMA-approved as add-on maintenance therapy for recurrent severe CRSwNP in adults who are inadequately controlled despite intranasal corticosteroids and FESS. It is not indicated for CRSsNP or for CRS in non-type-2-endotype patients.

Reference: Dhingra Diseases of Ear, Nose and Throat, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.